BioSpace News Archive

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in diabetic peripheral neuropathic pain, or DPNP.

Carmot Therapeutics, Inc. announced positive results from the following studies: a Phase 1 clinical trial of CT-388 assessing safety, tolerability, pharmacokinetics and pharmacodynamic activity in overweight and obese otherwise healthy participants and a preclinical study in rodent models of type 1 diabetes to support the effects of CT-868 as an adjunct to insulin treatment.

Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced data from its Phase 1b trial for INV-202 to be presented in a poster session at the 83rd American Diabetes Association Scientific Sessions (ADA) in San Diego.

Abcam plc, a global leader in the supply of life science research tools, announces that, having listened to and extensively engaged with shareholders, the Board of Directors has unanimously decided to initiate a process to explore strategic alternatives for the Company.

Jubilant Draximage Inc. and Evergreen Theragnostics, Inc announced a new agreement for Jubilant’s radiopharmacy business to prepare, sell, and distribute doses of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection) to positron emission tomography (PET) customers across the US. OCTEVYTM is pending approval by the United States Food & Drug Administration (FDA), which is expected in 2H 2023.

LUMINELLE, an innovative medical device company, announces a substantial marketing agreement with the U.S. Women’s Health Alliance, an organization focused on promoting high-quality, affordable healthcare for women.

GE HealthCare is set to unveil SIGNA PET/MR AIRi, at the Society of Nuclear Medicine and Molecular Imaging 2023 annual meeting.

Sonnet BioTherapeutics Holdings, Inc. announced today that John Cini, PhD, Chief Scientific Officer and Co-Founder, and Richard Kenney, MD, Chief Medical Officer, will be featured speakers at the 4th Annual Cytokine-Based Drug Development Summit in Boston, Massachusetts, June 27-29.

CMP Pharma, Inc. announced today that Atorvaliq (atorvastatin calcium) Oral Suspension, 20 mg/5 mL, the first and only FDA-approved oral liquid of atorvastatin, is now available.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the application for conditional marketing authorisation of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol).